CREBBP and neoplasm: Several reports demonstrated that both CBP-selective (ICG-001 and PRI-724) and CBP/p300 non-selective (C646) inhibitors are able to exert anti-tumor effects in CRC, counteracting β-Catenin binding and its transcriptional activity on WRE (Gaddis et al., 2015; Bordonaro and Lazarova, 2016).